Michael E. Prevoznik Sells 44,556 Shares of Quest Diagnostics Inc (NYSE:DGX) Stock

Quest Diagnostics Inc (NYSE:DGX) SVP Michael E. Prevoznik sold 44,556 shares of the company’s stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $107.43, for a total transaction of $4,786,651.08. Following the completion of the sale, the senior vice president now directly owns 51,321 shares of the company’s stock, valued at approximately $5,513,415.03. The sale was disclosed in a filing with the SEC, which is accessible through this link.

NYSE:DGX opened at $106.15 on Friday. The company has a fifty day moving average of $103.51 and a 200 day moving average of $102.17. Quest Diagnostics Inc has a 52 week low of $78.95 and a 52 week high of $108.30. The company has a quick ratio of 0.83, a current ratio of 0.88 and a debt-to-equity ratio of 0.56. The firm has a market capitalization of $14.23 billion, a P/E ratio of 16.82, a P/E/G ratio of 2.24 and a beta of 0.85.

Quest Diagnostics (NYSE:DGX) last announced its quarterly earnings results on Tuesday, October 22nd. The medical research company reported $1.76 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.71 by $0.05. Quest Diagnostics had a net margin of 9.58% and a return on equity of 15.32%. The business had revenue of $1.96 billion for the quarter, compared to analyst estimates of $1.94 billion. During the same quarter last year, the firm earned $1.68 EPS. The company’s revenue was up 3.5% on a year-over-year basis. As a group, analysts anticipate that Quest Diagnostics Inc will post 6.49 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 29th. Stockholders of record on Tuesday, January 14th will be paid a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a dividend yield of 2.00%. The ex-dividend date of this dividend is Monday, January 13th. Quest Diagnostics’s dividend payout ratio (DPR) is 33.60%.

A number of equities analysts recently commented on the stock. Evercore ISI reiterated a “buy” rating and issued a $108.00 target price on shares of Quest Diagnostics in a research report on Thursday, August 8th. ValuEngine lowered shares of Quest Diagnostics from a “hold” rating to a “sell” rating in a research report on Friday, November 29th. Canaccord Genuity reaffirmed a “buy” rating and set a $113.00 price objective on shares of Quest Diagnostics in a research note on Wednesday, October 23rd. UBS Group decreased their price objective on Quest Diagnostics from $103.00 to $102.00 and set a “neutral” rating on the stock in a report on Monday, October 21st. Finally, Morgan Stanley lifted their price objective on Quest Diagnostics from $111.00 to $121.00 and gave the stock an “overweight” rating in a report on Friday, August 23rd. Four equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and six have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $106.85.

Several institutional investors have recently bought and sold shares of DGX. Pearl River Capital LLC purchased a new position in Quest Diagnostics during the 2nd quarter valued at about $28,000. Wealthcare Advisory Partners LLC bought a new position in Quest Diagnostics during the 2nd quarter valued at approximately $29,000. Berman Capital Advisors LLC lifted its holdings in Quest Diagnostics by 47.7% in the 2nd quarter. Berman Capital Advisors LLC now owns 319 shares of the medical research company’s stock worth $32,000 after buying an additional 103 shares during the period. NuWave Investment Management LLC lifted its holdings in Quest Diagnostics by 108.4% in the 3rd quarter. NuWave Investment Management LLC now owns 346 shares of the medical research company’s stock worth $36,000 after buying an additional 180 shares during the period. Finally, Quest Capital Management Inc. ADV purchased a new stake in Quest Diagnostics in the 3rd quarter worth approximately $42,000. Institutional investors own 88.15% of the company’s stock.

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic testing information and services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.

Featured Story: Equal Weight Rating

Insider Buying and Selling by Quarter for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.